BioAgilytix has scaled its capabilities and geographical reach to become a premier independent global leader in bioanalytical testing, specialising in large molecule bioanalysis, benefitting from a best-in-class bioanalytical lab focusing on enabling all phases of biologics drug development from discovery through to commercial.
In less than three years, GHO completed a number of organic and inorganic investments in specific and strategically compelling areas such as cell & gene therapy, automation capabilities and laboratory information management systems.
BioAgilytix completed three value accretive add-on acquisitions expanding geographic footprint and strategic capabilities into high-value adjacencies.
